Cargando…
Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer
BACKGROUND: Almost all elderly patients with peritoneal metastatic gastric cancer (PGC) are unlikely to tolerate cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and adjuvant chemotherapy. However, determining how to optimize the treatment strategy for such patie...
Autores principales: | Chen, Zhi-Xiong, Li, Jin, Liu, Wen-Bin, Zhang, Shou-Ru, Sun, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855251/ https://www.ncbi.nlm.nih.gov/pubmed/35211587 http://dx.doi.org/10.12998/wjcc.v10.i5.1498 |
Ejemplares similares
-
Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
por: Spiegelberg, Julia, et al.
Publicado: (2020) -
Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study
por: Cashin, Peter H, et al.
Publicado: (2020) -
Repeated cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
por: Paasch, C., et al.
Publicado: (2021) -
Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative
por: Leiting, Jennifer L, et al.
Publicado: (2020) -
Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases
por: Steinhoff, Heinrich, et al.
Publicado: (2023)